Ukrainian Drone Makers Target Japan and Asia Defense Market 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
OXFORD, United Kingdom, Feb. 03, 2016 -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 | ||||
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 77148 7900 | ||||
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | ||||
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 [email protected] | ||||
| MacDougall Biomedical Communications (US media contact) Chris Erdman | Tel: +1 781 235 3060 [email protected] | ||||
-END-
